In August 2017, Canadian Blood Services changed its platelet product testing procedure to improve the detection of bacterial contamination. This change enhanced the safety of Canadian Blood Services platelet products and provided the opportunity to improve inventory management by extending the platelet shelf life from five to seven days.
“Paying it Forward: Why we need YOU to give blood" is an article by Dr. Jeannie Callum, a hospital-based transfusion specialist. Here she shares her real-life experience witnessing the impact of blood donation on patient lives. She provides some fascinating insight into blood transfusion, past and present, and emphasizes the need for male donors and why some donors may be safer for patients. This article is also being published in six parts on RED, our Research, Education and Discovery blog.
Current recommendations of the NAC indicate that the provision of CMV-seronegative and leukoreduced blood products is potentially required only in the setting of intrauterine transfusion. In October 2017, Canadian Blood Services will stop the testing donor blood for anti-CMV antibodies except for a small inventory of blood components tested for the sole purpose of intrauterine transfusion.
Decisions about blood safety need to take numerous factors into account, such as risks, benefits, costs, ethical issues, and stakeholder perspectives.
ABO has developed a unique framework to help blood service operators streamline the process and make responsible decisions that lead to the greatest good. Whether the blood safety decision to be made is small or large in scale, this framework can help to organize the process and to assure the quality of the information used to make the decision.
Canadian Blood Services delivers KnowledgeInfusion activities to disseminate research findings that are aligned with the goals of our organization in order to accelerate their uptake by the transfusion community. KnowledgeInfusion activities include Lunch&Learn webinars that are recorded and shared below.